Karyopharm Announces Five Clinical Data Presentations at ASCO

Karyopharm Therapeutics Inc.

, a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced that clinical and preclinical data for its lead drug candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from May 30 to June 3, 2014 in Chicago, Illinois. Clinical results to be presented include updated data from Karyopharm's Phase 1 studies in patients with advanced hematologic malignancies, solid tumors and sarcomas. Karyopharm will host an investor and analyst briefing Monday, June 2, 2014 in Chicago, Illinois at 6:30 p.m. CT. Oral Presentation: Saturday, May 31, 2014, 1:15 – 1:27 p.m. CT Title: A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients with heavily pretreated non-Hodgkin lymphoma (NHL). (Abstract #8518) Presenter: Martin Gutierrez, MD Location: E Arie Crown Theater Poster Presentations: Friday, May 30, 2014, 1:00 – 4:00 p.m. CT (poster highlights presentation) Title: A first-in-class, first-in-human phase 1 trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients with advanced solid tumors. (Abstract #2537) Presenter: Morten Mau-Soerensen, MD, PhD Poster Display: E354b, Poster Board #52 Discussion: 4:30-5:45p.m. CT, E Arie Crown Theater Saturday, May 31, 2014, 1:15 – 4:15 p.m. CT (poster highlights presentation) Title: A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients with relapsed/refractory acute myeloid leukemia (AML). (Abstract #7032) Presenter: Karen W. L. Yee, MD Poster Display: S405, Poster Board #24 Discussion: 4:45-6:00p.m. CT, S406 Monday, June 2, 2014, 8:00 – 11:45 a.m. CT (poster presentation) Title: A phase 1b food effect study of the first-in-class, oral, selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients with advanced sarcomas. (Abstract #10587) Presenter: Mrinal M. Gounder, MD Poster Display: E354b, Poster Board #294 Monday, June 2, 2014, 8:00 – 11:00 a.m. CT (poster highlights presentation) Title: Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients with platinum resistant/refractory ovarian cancer (OvCa). (Abstract #5522) Presenter: John Martignetti, MD, PhD Poster Display: E354b, Poster Board #11 Discussion: 11:30-12:45 p.m. CT, Room E354a About Selinexor Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor functions by binding with the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. To date, approximately 300 patients have been treated with Selinexor in Phase 1 and 2 trials in advanced hematologic malignancies and solid tumors. Additional Phase 1 and Phase 2 studies are ongoing or currently planned and three registration-directed clinical trials in hematological indications are expected to begin enrollment during 2014. The latest clinical trial information for Selinexor is available at www.clinicaltrials.gov.